Orexo
Orexo AB, a leading pharmaceutical company headquartered in Sweden, focuses on developing innovative treatments for addiction and pain management. Founded in 1995, Orexo has established a strong presence in Europe and North America, with a commitment to addressing unmet medical needs through advanced drug delivery technologies. The company’s core products, including Zubsolv, a sublingual film for opioid dependence, exemplify its unique approach to patient care. Orexo's dedication to research and development has positioned it as a key player in the pharmaceutical industry, with notable achievements in improving treatment outcomes for patients struggling with addiction. With a robust pipeline and a focus on sustainable growth, Orexo continues to make significant strides in enhancing the quality of life for individuals facing complex health challenges.
DitchCarbon Score
How does Orexo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orexo's score of 24 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Orexo's reported carbon emissions
In 2023, Orexo reported total carbon emissions of approximately 1,660,000 kg CO2e. This figure includes 273,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 73,000 kg CO2e from Scope 2 emissions, related to the purchase of electricity. The majority of their emissions, about 1,314,000 kg CO2e, fall under Scope 3, which includes indirect emissions from the value chain. In 2022, Orexo's total emissions were about 1,845,000 kg CO2e, indicating a reduction of approximately 185,000 kg CO2e in 2023. This reduction reflects their ongoing commitment to improving sustainability practices, although specific reduction targets or initiatives have not been disclosed. Orexo's emissions profile highlights the significant impact of Scope 3 emissions, which are critical for companies in the pharmaceutical industry to address. While no formal climate pledges or science-based targets have been established, the company is actively monitoring and reporting its emissions, demonstrating a commitment to transparency and accountability in its climate efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 284,000 | 000,000 |
| Scope 2 | 73,000 | 00,000 |
| Scope 3 | 1,488,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orexo is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
